Eden vs MEDVi (2026): prices, structure, verdict

On tirzepatide, MEDVi↗ is cheaper: $399 versus $408 a month all-in — a $9 monthly gap, $108 across a year of maintenance dosing, and MEDVi's figure is dose-flat while Eden's structure is not.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Eden is cheaper: $198 versus $299 a month all-in — a $101 monthly gap, $1,212 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Eden: the record, condensed

Start with the load-bearing figure: $408 a month, all-in, is what Eden charges for tirzepatide at the 10 mg basis. Pricing steps with the dose here: from $348 at entry to $408 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $720 a year, which is why every ranking on this site uses the larger number.

The all-in figure already contains a compulsory $99 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $309 would be exactly that kind of mirage.

Context for that figure: it ranks #16 of 17 in the verified tirzepatide index — $193/month above the floor (NexLife↗, $215) — and sits $41 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $4,896.

Eden’s semaglutide program bills $198 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Eden is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

A required $99/month membership is part of the deal, and part of the figure above: $99 of medication plus $99 of platform equals the $198 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #10 of 20 verified programs, with the floor $65/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $151 a month. A year at this figure: $2,376 monthly-billed.

Operationally at Eden: shipping included; commitment membership auto-renews; cancellation membership auto-renews until cancelled; pharmacy not publicly named — ask in writing before paying; states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Eden page · visit Eden ↗

MEDVi: the record, condensed

Start with the load-bearing figure: $399 a month, all-in, is what MEDVi charges for tirzepatide at the 10 mg basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #14 of 17 in the verified tirzepatide index — $184/month above the floor (NexLife, $215) — and sits $50 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,788.

Start with the load-bearing figure: $299 a month, all-in, is what MEDVi charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.

To place the number: #18 of 20 verified programs, with the floor $166/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $50 a month. A year at this figure: $3,588 monthly-billed.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $399 (MEDVi) against $408 (Eden). $9 a month sounds survivable; $108 a year is a decision.

Structure sharpens the gap: MEDVi’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while Eden’s is not — so MEDVi’s number is a ceiling and Eden’s advertised entry ($348) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Eden’s total includes a mandatory $99/month membership; MEDVi has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: Eden at $198, MEDVi at $299 — a $101 monthly spread that compounds to $1,212 over a maintenance year and $2,424 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $101 gap is exactly what it appears to be.

Eden’s total includes a mandatory $99/month membership; MEDVi has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Translate the $9/month spread into medication: $108 a year equals roughly 0.3 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: Eden $408/mo month-to-month versus MEDVi $399/mo month-to-month. Same winner on both bases — MEDVi leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Eden $1,224 monthly; MEDVi $1,197 monthly — best path favors MEDVi by $27. 6 months: Eden $2,448 monthly; MEDVi $2,394 monthly — best path favors MEDVi by $54. 12 months: Eden $4,896 monthly; MEDVi $4,788 monthly — best path favors MEDVi by $108. 24 months: Eden $9,792 monthly; MEDVi $9,576 monthly — best path favors MEDVi by $216.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Eden $594 vs MEDVi $897 — $303 to Eden. 6 mo: Eden $1,188 vs MEDVi $1,794 — $606 to Eden. 12 mo: Eden $2,376 vs MEDVi $3,588 — $1,212 to Eden. 24 mo: Eden $4,752 vs MEDVi $7,176 — $2,424 to Eden.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Eden publishes “most states”; MEDVi publishes “priced differently in CA/NC on some plans” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Eden — membership auto-renews; membership auto-renews until cancelled. MEDVi — 12-month plan for the lowest rate; 12-month plan applies to lowest rate.

Evidence: Eden source-verified (captured 2026-08-05); MEDVi source-verified (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

In the full tirzepatide index these two sit at #16 and #14 of 17: between them lie 1 other program, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #10 and #18 of 20: between them lie 7 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Eden and MEDVi

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Eden: membership auto-renews until cancelled; MEDVi: 12-month plan applies to lowest rate) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings